GLP1R and metabolic dysfunction-associated steatotic liver disease: Multiple cell‐based and animal‐based (e.g., mouse model) experiments, as well as clinical trials, have suggested that GLP‐1R could be a potential target for MASLD treatment, although its mechanism of action remains unclear.[25] We propose that human zonated MASLD organoids could be utilized to verify the effects of GLP‐1RA drugs and conduct related mechanistic investigation.